DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for brain glioblastoma — screening already-approved drugs against its 48-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleBrain glioblastoma maps to a 48-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for brain glioblastoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-activated catalytic subunit alpha (PRKACA) — PRKACA is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1edrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3OVV · 1.58 Å · ligand N'-[(1E)-(4-hydroxyphenyl)methylidene]-2-(3-methoxyphenyl)acetohydrazide (1SB). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Oncology · 2003 · 111 citations
Recent advances in the molecular genetics of primary gliomas
AbstractPrimary brain tumors, particularly glioblastomas, remain a challenge for oncology. Uncontrolled cellular proliferation, lack of apoptosis, invasion, and angiogenesis are among the biologic processes that render these tumors both aggressive and difficult to treat. An understanding of the genetics and molecular events regulating these aggressive tumors is beginning to emerge, partly because of recent knowledge in genomics, gene expression analysis, and mouse tumor models. As a result, it is now generally accepted that brain tumors, particularly those arising from cells of glial lineage, result from stepwise accumulation of deleterious genetic alterations. Several genetic abnormalities have been described, and current research is aimed at elucidating their causal association with brain tumor formation and progression. The purpose of this review is to summarize some of the most important recently published findings on the molecular genetics of primary gliomas.
British Journal of Clinical Pharmacology · 2015 · 44 citations · open access
Repurposing some older drugs that cross the blood–brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma
AbstractGlioblastoma is a brain neoplasm with limited 5-year survival rates. Developments of new treatment regimens that improve patient survival in patients with glioblastoma are needed. It is likely that a number of existing drugs used in other conditions have potential anticancer effects that offer significant survival benefit to glioblastoma patients. Identification of such drugs could provide a novel treatment paradigm.
Tidsskrift for Den norske legeforening · 2023 · 1 citations · open access
Glioblastom hos voksne
AbstractGlioblastoma is the most common form of primary brain cancer in adults, and the disease has a serious prognosis. Although great progress has been made in molecular characteristics, no major breakthroughs in treatment have been achieved for many years. In this article we present a clinical review of current diagnostics and treatment, as well as the challenges and opportunities inherent in developing improved and more personalised treatment.
AbstractOver the years, there has been significant expansion in therapy modalities studied in patients with glioblastoma. These therapies include, but are not limited to, targeted molecular therapies, DNA repair pathway targeted therapies, immunotherapies, vaccine therapies, and surgically targeted radiotherapies. Glioblastoma is the most common malignant primary brain tumor in adults and unfortunately remains with poor overall survival following the current standard of care. Given the dismal prognosis, significant clinical and research efforts are ongoing with the goal of improving patient outcomes and enhancing quality and quantity of life utilizing a wide variety of novel therapies.
Advances in bioinformatics and biomedical engineering book series · 2023 · 0 citations
Glioblastoma
AbstractGlioblastoma is the most aggressive primary malignant brain tumor in adults. Complex genetic and molecular changes that cause unchecked cell proliferation, invasion of the surrounding brain tissue, and angiogenesis are the hallmarks of the physiopathology of glioblastoma. Although there are treatment options for this deadly tumor that include surgery, radiation, and chemotherapy, the blood-brain barrier and the tumor's infiltrative nature restrict their effectiveness, frequently leading to tumor recurrence and illness progression. To create new therapeutic approaches and enhance patient outcomes, it is crucial to comprehend the physiopathology of glioblastoma and its associated consequences. To improve treatment and quality of life for patients with glioblastoma, further research is required to clarify molecular causes, discover therapeutic targets, and address the difficulties provided by comorbidities.
Journal of Diseases Disorders & Treatments · 2022 · 0 citations · open access
Glioblastomas - Study Using Molecular Markers
AbstractGlioblastoma is a lethal tumor that can develop in the central nervous system. The most serious type of brain cancer is known as glioblastoma multiforme (GBM). This work aims to emphasize the usage of different glioblastoma markers during the diagnosis process and the treatment of the GBM. And also this may focus on the changes that are often associated with GBM pathogenesis and understanding the significance of glioblastoma markers, as well as their involvement in numerous critical cellular signaling pathways, can help direct potential research toward novel GBM treatments.
Current and Future Perspective of Glioblastoma, Molecular Heterogeneity with Clinical case
AbstractGlioblastoma multiforme is a highly vascular most common primary brain tumor which isextremely narcissistic in its character and function. It has high rates of recurrence despite neurosurgery,chemotherapy targeted therapy and radiotherapy. It is diligent endeavor of neurosurgeon andneurooncologist to make decision for patients who present with recurrence of this evil disease manytimes. This article is an attempt to delineate clinical spectrum molecular types character of this diseasewith a clinical experience of professionals dealing with this glioblastoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works using Disease Ontology synonyms, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
